RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 146 filers reported holding RECURSION PHARMACEUTICALS IN in Q3 2022. The put-call ratio across all filers is 0.32 and the average weighting 2.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $76,745 | -6.8% | 10,032 | -9.0% | 0.05% | -4.1% |
| Q2 2023 | $82,379 | +11.4% | 11,028 | -0.5% | 0.05% | +19.5% |
| Q1 2023 | $73,937 | -37.5% | 11,085 | -27.7% | 0.04% | -33.9% |
| Q4 2022 | $118,287 | -33.9% | 15,342 | -8.9% | 0.06% | -12.7% |
| Q3 2022 | $179,000 | +31.6% | 16,847 | +0.7% | 0.07% | +42.0% |
| Q2 2022 | $136,000 | +126.7% | 16,726 | +101.0% | 0.05% | +85.2% |
| Q1 2022 | $60,000 | -60.3% | 8,321 | -5.7% | 0.03% | -52.6% |
| Q4 2021 | $151,000 | – | 8,821 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Obvious Management Services, L.L.C. | 5,977,631 | $42,800,000 | 100.00% |
| Two Sigma Ventures, LP | 1,806,800 | $12,937,000 | 74.73% |
| DCVC Opportunity Fund II GP, LLC | 3,951,141 | $28,290,000 | 31.54% |
| MV Management XI, L.L.C. | 1,971,908 | $14,119,000 | 9.80% |
| Data Collective IV GP, LLC | 5,941,120 | $42,538,000 | 9.03% |
| ArchPoint Investors | 1,267,430 | $9,075,000 | 3.13% |
| MIC Capital Management UK LLP | 1,388,889 | $9,944,000 | 1.94% |
| HARVARD MANAGEMENT CO INC | 1,509,254 | $10,806,000 | 1.09% |
| Samsara BioCapital, LLC | 539,236 | $3,861,000 | 0.97% |
| Pinz Capital Management, LP | 142,168 | $1,018,000 | 0.64% |